GI Biome has changed its company name to GI Longevity and is entering the anti-aging bio market. The name change was approved at last Friday’s shareholder meeting. Through the name change, the company plans to focus on the anti-aging market.

GI Longevity has been developing anti-aging therapies utilizing its core microbiome technology, GIB-7, through preclinical and research studies that have demonstrated muscle strength enhancement, improved sleep quality in older adults, and enhanced quality of life in colorectal cancer patients after surgery.

The company is preparing clinical trials in Australia and Korea in collaboration with GAI Innovation, targeting older adults with a combination therapy of GI-102 (an immunotherapy) and GIB-7 (a microbiome-based compound).

Along with the name change, the company is also developing additional pipelines using various modalities to enhance immune function, cognitive function, and muscle strength, which are core pillars of anti-aging. Furthermore, by combining the unique approaches of its affiliate companies, including GI Innovation's low-dose immunotherapy GI-102 and GI Cell's autologous NK cell therapy, the company aims to maximize synergy toward the goal of extending healthy lifespan.

“This name change is not merely a superficial alteration but a milestone declaring our new corporate identity and direction to the world,” GI Longevity CEO Yang Bo-gie said. “Through our participation in the XPRIZE finals next year, we aim to accelerate the commercialization and business development of technologies for extending healthy lifespan and establish ourselves as a leading global company in the anti-aging industry.”